高旸,丁嵩,何奔

• 1:上海交通大学医学院附属仁济医院心内科

摘要(Abstract)：

<正>近年来,以经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI)为主要代表的介入治疗已经逐渐成为冠心病治疗的主要方法之一。而PCI术使用的支架也在不断的改进和创新,已从最早的裸金属支架(bare metal stent,BMS)发展到药物洗脱支架(drug-eluting stent,DES)。DES作为冠状动脉狭窄血运重建治疗的选择之一被写入了《2012年美国心脏病学会基金会(American College of

关键词(KeyWords)： 生物可吸收支架;经皮冠状动脉介入治疗;药物洗脱支架

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金项目(81400261)

作者(Author): 高旸,丁嵩,何奔

参考文献(References)：

• [1]Fihn SD,Gardin JM,Abrams J,et al.2012 ACCF/ACC/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,and the American College of Physicians,American Association for Thoracic Surgery,Preventive Cardiovascular Nurses Association,Society for Cardiovascular Angiography and Interventions,and Society of Thoracic Surgeons.J Am Coll Cardiol,2012,60(24):e44-164.
• [2]Montalescot G,Sechtem U,Achenbach S,et al.2013 ESC guidelines on the management of stable coronary artery disease:the Task Force on the management of stable coronary artery disease of the European Society of Cardiology.Eur Heart J,2013,34(38):2949-3003.
• [3]Wiebe J,Nef HM,Hamm CW.Current Status of Bioresorbable Scaffolds in the Treatment of Coronary Artery Disease.J Am Coll Cardiol,2014,64(23):2541-2551.
• [4]Kereiakes DJ,Ellis SG,Popma JJ,et al.Evaluation of a fully bioresorbable vascular scaffold in patients with coronary artery disease:design of and rationale for the ABSORB III randomized trial.Am Heart J,2015,170(4):641-651.
• [5]Kimura T,Kozuma K,Tanabe K,et al.A randomized trial evaluating everolimus-eluting ABSORBbioresorbable scaffolds vs.everolimus-eluting metallic stents in patients with coronary artery disease:ABSORB Japan.Eur Heart J,2015,36(47):3332-3342.
• [6]Gao R,Yang Y,Han Y,et al.Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients With Coronary Artery Disease:ABSORB China Trial.J Am Coll Cardiol,2015,66(21):2298-2309.
• [7]Puricel S,Arroyo D,Corpataux N,et al.Comparison of everolimus-and biolimus-eluting coronary stents with everolimuseluting bioresorbable vascular scaffolds.J Am Coll Cardiol,2015,65(8):791-801.
• [8]Waksman R.Biodegradable stents:they do their job and disappear.J Invasive Cardiol,2006,18(2):70-74.
• [9]Muramatsu T,Onuma Y,Zhang YJ,et al.Progress in treatment by percutaneous coronary intervention:the stent of the future.Rev Esp Cardiol(Engl Ed),2013,66(6):483-496.
• [10]Mauri L,Hsieh WH,Massaro JM,et al.Stent thrombosis in randomized clinical trials of drug-eluting stents.N Engl J Med,2007,356(10):1020-1029.
• [11]Applegate RJ,Sacrinty MT,Little WC,et al.Incidence of coronary stent thrombosis based on academic research consortium definitions.Am J Cardiol,2008,102(6):683-688.
• [12]Riegger J,Byrne RA,Joner M,et al.Histopathological evaluation of thrombus in patients presenting with stent thrombosis.A multicenter European study:a report of the prevention of late stent thrombosis by an interdisciplinary global European effort consortium.Eur Heart J,2016,37(19):1538-1549.
• [13]Heublein B,Rohde R,Kaese V,et al.Biocorrosion of magnesium alloys:a new principle in cardiovascular implant technology?Heart,2003,89(6):651-656.
• [14]Waksman R,Pakala R,Kuchulakanti PK,et al.Safety and efficacy of bioabsorbable magnesium alloy stents in porcine coronary arteries.Catheter Cardiovasc Interv,2006,68(4):607-617.
• [15]Wentzel JJ,Whelan DM,van der Giessen WJ,et al.Coronary stent implantation changes 3-D vessel geometry and 3-D shear stress distribution.J Biomech,2000,33(10):1287-1295.
• [16]Togni M,Windecker S,Cocchia R,et al.Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction.J Am Coll Cardiol,2005,46(2):231-236.
• [17]Gomez-Lara J,Brugaletta S,Farooq V,et al.Angiographic geometric changes of the lumenarterial wall after bioresorbable vascular scaffoldsand metallic platform stents at 1-year follow-up.JACC Cardiovasc Interv,2011,4(7):789-799.
• [18]Brugaletta S,Radu MD,Garcia-Garcia HM,et al.Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation:can the scaffold cap the plaque?Atherosclerosis,2012,221(1):106-112.
• [19]Ielasi A,Tespili M.Current and future perspectives on drugeluting bioresorbable coronary scaffolds.Future Cardiol,2014,10(3):409-420.
• [20]Caiazzo G,Kilic ID,Fabris E,et al.ABSORB bioresorbable vascular scaffold:What have we learned after 5 years of clinical experience?Int J Cardiol,2015,201:129-136.
• [21]Stone GW,Gao R,Kimura T,et al.1-year outcomes with the ABSORB bioresorbablescaffold in patients with coronary artery disease:a patient-level,pooled meta-analysis.Lancet,2016,387(10025):1277-1289.
• [22]Cassese S,Byrne RA,Ndrepepa G,et al.Everolimus-eluting bioresorbable vascular scaffolds versuseverolimus-eluting metallic stents:a meta-analysis ofrandomised controlled trials.Lancet,2016,387(10018):537-544.
• [23]Tanaka A,Ruparelia N,Kawamoto H,et al.Clinical outcomes following bioresorbable scaffold implantation insmall vessels.Int J Cardiol,2016,207:59-61.
• [24]Giacchi G,Ortega-Paz L,Brugaletta S,et al.Bioresorbable vascular scaffold implantation in acute coronary syndromes:clinical evidence,tips and tricks.Postepy Kardiol Interwencyjnej,2015,11:161-169.
• [25]Onuma Y,Serruys PW,Ormiston JA,et al.Three-year results of clinical follow-up after a bioresorbableeverolimus eluting scaffold in patients with de novo coronary artery disease:the ABSORB trial.Euro Intervention,2010,6(4):447-453.
• [26]Ielasi A,Varricchio A,Campo G,et al.A prospective evaluation of a standardized strategy for the use of a polymeric everolimuseluting bioresorbable scaffold in ST-segment elevation myocardial infarction:Rationale and design of the BVS STEMI STRATEGYIT study.Catheter Cardiovasc Interv,2016[Epub ahead of print].
• [27]于一,赵迎新,史冬梅,等.生物可吸收支架的最新研究进展.中国介入心脏病学杂志,2016,24(9):521-525.
• [28]周学敏,吕慧,朱国斌.生物可吸收支架临床研究进展.中国介入心脏病学杂志,2015,23(11):643-646.